2. Search Result
Search Result
Results for "

livers

" in MedChemExpress (MCE) Product Catalog:

1800

Inhibitors & Agonists

14

Screening Libraries

14

Fluorescent Dye

55

Biochemical Assay Reagents

53

Peptides

6

MCE Kits

14

Inhibitory Antibodies

430

Natural
Products

135

Isotope-Labeled Compounds

3

Click Chemistry

43

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124899
    Hh-Ag1.5
    1 Publications Verification

    SAg1.5

    		 Hedgehog Metabolic Disease
    Hh-Ag1.5 (SAg1.5) is a potent Hedgehog (Hh) agonist with an EC50 of 1 nM . Hh-Ag1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure .
    Hh-Ag1.5
  • HY-W414823
    24,25-Epoxycholesterol

    		LXR HMG-CoA Reductase (HMGCR) Metabolic Disease
    24,25-Epoxycholesterol is an oxysterol agonist of the liver X receptor that can inhibit the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) in liver cells. 24,25-Epoxycholesterol regulates cholesterol metabolism in the liver .
    24,25-Epoxycholesterol
  • HY-134221
    S-Nitroso-N-acetylcysteine

    		Adrenergic Receptor Reactive Oxygen Species (ROS) Cardiovascular Disease
    S-Nitroso-N-acetylcysteine is a nitric oxide donor. S-Nitroso-N-acetylcysteine has a tissue vascular dilation effect, which can enhance liver microcirculation and effectively prevent ischemia-reperfusion injury in fatty liver. S-Nitroso-N-acetylcysteine can reduce liver fibrosis in rats with cirrhosis .
    S-Nitroso-N-acetylcysteine
  • HY-101473A
    EMD527040 hydrochloride

    		Integrin Cancer
    EMD527040 (hydrochloride) is a highly potent and selective αvβ6 antagonist with anti-fibrotic activity. EMD527040 (hydrochloride) is used in the research of liver cancer and liver fibrosis .
    EMD527040 hydrochloride
  • HY-157650
    HSD17B13-IN-20

    		17β-HSD Metabolic Disease
    HSD17B13-IN-38 (Compound 18.02) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
    HSD17B13-IN-20
  • HY-157654
    HSD17B13-IN-26

    		17β-HSD Metabolic Disease
    HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
    HSD17B13-IN-26
  • HY-157653
    HSD17B13-IN-22

    		17β-HSD Metabolic Disease
    HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
    HSD17B13-IN-22
  • HY-N4063
    Hedragonic acid

    		FXR Inflammation/Immunology
    Hedragonic acid is an oleane-type triterpenoid compound, which can be isolated from the stems and roots of the southern snake vine. Hedragonic acid is a ligand and agonist for FXR. Hedragonic acid protected mice from liver damage caused by acetaminophen overdose and reduced liver inflammation .
    Hedragonic acid
  • HY-160064
    SW1-A aptamer sodium

    		DNA Alkylator/Crosslinker Cancer
    SW1-A aptamer sodium is an optimized aptamer based on SW1 aptamer (HY-160063) that specifically targets liver cancer SMMC-7721 cells (Kd: 133.73 nM). SW1-A aptamer maintains strong affinity to liver cancer tissues and cells .
    SW1-A aptamer sodium
  • HY-W587771
    Mono-2-ethyl-5-carboxypentyl terephthalate

    MECPTP

    		 Drug Metabolite Metabolic Disease
    Mono-2-ethyl-5-carboxypentyl terephthalate (MECPTP) is a major metabolite of Di-2-ethylhexyl terephthalate (DEHTP). Mono-2-ethyl-5-carboxypentyl terephthalate is promising for research of metabolic liver diseases, such as nonalcoholic fatty liver disease (NAFLD) .
    Mono-2-ethyl-5-carboxypentyl terephthalate
  • HY-168332
    FXR agonist 11

    		FXR Metabolic Disease
    FXR agonist 11 (Compound 14) is an FXR agonist with an EC50 of 1.2 μM and a maximum effect of 73.7%. FXR agonist 11 can significantly increase GSH levels in the liver and is used to study drug-induced liver injury diseases .
    FXR agonist 11
  • HY-172087
    VDR agonist 3

    		VD/VDR Inflammation/Immunology
    VDR agonist 3 (Compound E15) is a potent vitamin D receptor (VDR) agonist. VDR agonist 3 can effectively inhibit HSC activation through VDR. VDR agonist 3 significantly reduces liver fibrosis without causing hypercalcemia in a CCl4-induced mouse liver fibrosis model .
    VDR agonist 3
  • HY-N7541
    Antrodin A

    		Others Inflammation/Immunology
    Antrodin A is one of the main active ingredients in the solid-state fermented A. camphorate mycelium. Antrodin A protects the liver from alcohol damage by improving the antioxidant and anti-inflammatory capacity of the liver and maintaining the stability of the intestinal flora .
    Antrodin A
  • HY-133860
    Chrysoobtusin

    		Drug Derivative Others
    Chrysoobtusin is an anthraquinone derivative isolated from Semen Cassiae. Semen Cassiae has long been used to protect liver, brighten eyes, and relieve constipation .
    Chrysoobtusin
  • HY-162220
    HSD17B13-IN-94

    		Estrogen Receptor/ERR 17β-HSD Metabolic Disease
    HSD17B13-IN-94 (Compound 12) is an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for Estradiol (HY-B0141). HSD17B13-IN-94 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD, NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-94
  • HY-10327
    GW-6604

    		TGF-β Receptor Metabolic Disease
    GW-6604 is an ALK5 inhibitor with an IC50 value of 140 nM for inhibiting its autophosphorylation, and can be used in the study of liver fibrosis .
    GW-6604
  • HY-42682
    D(+)-Galactosamine hydrochloride
    2 Publications Verification

    D-Galactosamine HCl

    		 Drug Derivative Inflammation/Immunology
    D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .
    D(+)-Galactosamine hydrochloride
  • HY-N7390
    Cholesterol glucuronide

    		Endogenous Metabolite Metabolic Disease
    Cholesterol glucuronide is an endogenous metabolite of lipid generated in the liver by UDP glucuonyltransferase .
    Cholesterol glucuronide
  • HY-149835
    TTX-P

    		Fluorescent Dye Others
    TTX-P is a fluorescent probe. TTX-P responds in situ to the overexpressed alkaline phosphatase (ALP) in liver, imaging of diabetic liver injury in the near-infrared second-window (NIR-II) region .
    TTX-P
  • HY-119669
    Furylfuramide

    		Bacterial Others
    Furylfuramide is a food preservative that exhibits mutagenic activity. Furylfuramide can be degraded through the aerobic metabolism by liver microsomes .
    Furylfuramide
  • HY-152860
    Darizmetinib

    HRX-0215

    		 p38 MAPK JNK NF-κB MDM-2/p53 Cancer
    Darizmetinib (HRX-0215) is an orally active, potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4). Darizmetinib leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Darizmetinib is promising for research of preventing liver failure after extensive oncological liver resections or transplantation of small liver grafts .
    Darizmetinib
  • HY-161851
    MDL3

    		Phosphodiesterase (PDE) Metabolic Disease
    MDL3 is a novel inhibitor of PDE4B and PDE5A. MDL3 against liver injury and inflammation and inhibits the pathological remodeling of adipose tissue .
    MDL3
  • HY-122916
    7-Acetyllycopsamine

    		Others Metabolic Disease Inflammation/Immunology
    7-Acetyllycopsamine, a pyrrolizidine alkaloid, is a mild hepatotoxin. 7-Acetyllycopsamine can induce liver inflammation in mice .
    7-Acetyllycopsamine
  • HY-162378
    LT-630

    		HDAC Inflammation/Immunology
    LT-630 is a HDAC6 inhibitor. LT-630 ameliorates liver injury by reducing oxidative damage .
    LT-630
  • HY-123899
    Cleomiscosin B

    		HIV Others
    Cleomiscosin B, a coumarinolignoid, is could isloted from the seeds of Hyoscyamus niger. Cleomiscosin B has potent liver protective .
    Cleomiscosin B
  • HY-141749A
    Clopidogrel carboxylic acid

    CLPM; SR 26334

    		 Endogenous Metabolite Metabolic Disease
    Clopidogrel carboxylic acid (CLPM) is the inactive liver metabolite of anti platelet agent, Clopidogrel (HY-15283), in human serum .
    Clopidogrel carboxylic acid
  • HY-45131
    Cholesterol absorption inhibitor 1

    		Drug Intermediate Metabolic Disease
    Cholesterol absorption inhibitor 1 (compound 21) is a cholesterol absorption inhibitor that reduces liver cholesteryl ester .
    Cholesterol absorption inhibitor 1
  • HY-169004
    CBT-295

    		TGF-beta/Smad Interleukin Related Neurological Disease Inflammation/Immunology
    CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy .
    CBT-295
  • HY-19586
    Albifylline

    A 81-3138; HWA-138

    		 Phosphodiesterase (PDE) Endocrinology
    Albifylline (A 81-3138; HWA-138) is a Xanthine (HY-W017389) derivate. Albifylline reduces the shock-induced leukocyte adhesions to the sinusoidal endothelium in the liver after hemorrhagic shock and improves microvascular blood flow in the liver .
    Albifylline
  • HY-42682R
    D(+)-Galactosamine hydrochloride (Standard)

    D-Galactosamine HCl (Standard)

    		 Reference Standards Inflammation/Immunology
    D(+)-Galactosamine (hydrochloride) (Standard) is the analytical standard of D(+)-Galactosamine (hydrochloride). This product is intended for research and analytical applications. D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .
    D(+)-Galactosamine hydrochloride (Standard)
  • HY-174253
    HSD17B13-IN-105

    		17β-HSD Metabolic Disease
    HSD17B13-IN-105 (Compound EX.87) is a selective 17β-hydroxysteroid dehydrogenase 13 (17BHSD13) inhibitor with an IC50 value of 0.036 μM, showing high selectivity over 17BHSD4 (with an IC50 value of 31.5 μM). HSD17B13-IN-105 is promising for research of liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) .
    HSD17B13-IN-105
  • HY-N12069
    Praeroside IV

    		Others Inflammation/Immunology
    Praeroside IV can be isolated from the roots of Angelica furcijuga. Praeroside IV can be used for research of D-GalN/LPS-induced liver injury .
    Praeroside IV
  • HY-D0075
    DHPDS disodium salt

    		Fluorescent Dye Others
    DHPDS disodium salt is a pH-sensitive fluorescent dye. DHPDS disodium salt is used to measure intracellular pH (pHi) from the surface fluorescence of the isolated perfused rat liver .
    DHPDS disodium salt
  • HY-174805
    THRβ receptor agonist-2

    		Thyroid Hormone Receptor Metabolic Disease
    THRβ receptor agonist-2 (Example 7-4) is a THRβ receptor agonist. THRβ receptor agonist-2 can be used for research of liver disorder or a cardiometabolic disease .
    THRβ receptor agonist-2
  • HY-108571
    CP-775146

    		PPAR Cardiovascular Disease Metabolic Disease
    CP-775146 is a selective PPARα agonist (Ki of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .
    CP-775146
  • HY-16718
    Dagrocorat

    PF-00251802

    		 Glucocorticoid Receptor Cytochrome P450 Inflammation/Immunology Endocrinology
    Dagrocorat (PF-00251802) is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor. Dagrocorat is also a time-dependent reversible inhibitor of CYP3A (IC50=1.3 μM in human liver microsomes) and CYP2D6 (Ki=0.57 μM in human liver microsomes). Dagrocorat can be used for the research of rheumatoid arthritis .
    Dagrocorat
  • HY-16718A
    Dagrocorat hydrochloride

    PF-00251802 hydrochloride

    		 Glucocorticoid Receptor Cytochrome P450 Inflammation/Immunology Endocrinology
    Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor. Dagrocorat hydrochloride is also a time-dependent reversible inhibitor of CYP3A (IC50=1.3 μM in human liver microsomes) and CYP2D6 (Ki=0.57 μM in human liver microsomes). Dagrocorat hydrochloride can be used for the research of rheumatoid arthritis .
    Dagrocorat hydrochloride
  • HY-127166
    Colchiceine

    O10-Demethylcolchicine

    		 Microtubule/Tubulin Inflammation/Immunology
    Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis .
    Colchiceine
  • HY-W037893
    METTL3 activator-1

    		METTL3 Inflammation/Immunology
    METTL3 activator-1 (2-Piperazinecarboxylic acid methyl ester dihydrochloride) is a Mettl3 activator that can promote the expression of Mettl3. METTL3 activator-1 can be used for the study of liver fibrosis .
    METTL3 activator-1
  • HY-W006566A
    5-AIQ hydrochloride

    5-Aminoisoquinolin-1-one hydrochloride

    		 PARP Cancer
    5-AIQ hydrochloride is a PARP-1 inhibitor. 5-AIQ hydrochloride is an important functional group in various drugs. 5-AIQ hydrochloride reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver .
    5-AIQ hydrochloride
  • HY-170571
    BE2647

    		Mitochondrial Metabolism Metabolic Disease Inflammation/Immunology
    BE2647 is a selective inhibitor for mitochondrial pyruvate carrier (MPC) with an EC50 of 70 nM. BE2647 exhibits good metabolic stability in mouse liver microsomes. BE2647 can be used in research of metabolic diseases, non-alcoholic fatty liver disease (MASLD), or non-alcoholic steatohepatitis (MASH) .
    BE2647
  • HY-167643
    Hydroxy tipelukast

    		Drug Metabolite Metabolic Disease Inflammation/Immunology
    Hydroxy tipelukast (Compound MN-002), the metabolite of Compound MN-001, is an orally active phenoxyalkylcarboxylic acid. Hydroxy tipelukast inhibits liver steatosis, lobular inflammation, hepatic ballooning, and hepatic scarring, and reduces liver hydroxyproline levels. Hydroxy tipelukast is promising for research of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) .
    Hydroxy tipelukast
  • HY-171857
    Cytaphat

    		Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology
    Cytaphat is a compound with hepatoprotective activity. Cytaphat has antioxidant, membrane-stabilizing and choleretic effects. Cytaphat can be used in the research of diseases such as acute toxic hepatopathy and liver injury .
    Cytaphat
  • HY-143259
    BE1218

    		LXR Cancer
    BE1218 is a liver X receptor (LXR) inverse agonist with IC50 values of 9 nM and 7 nM against LXRα and LXRβ, respectively .
    BE1218
  • HY-157613
    HSD17B13-IN-5

    		17β-HSD Metabolic Disease
    HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-5
  • HY-157601
    HSD17B13-IN-4

    		17β-HSD Metabolic Disease
    HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-4
  • HY-139607
    SSAO inhibitor-1

    		Monoamine Oxidase Inflammation/Immunology
    SSAO inhibitor-1 is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor. SSAO inhibitor-1 has anti-inflammatory activity and can be used for liver diseases research .
    SSAO inhibitor-1
  • HY-145624A
    Obeversen sodium

    ION-769357 sodium

    		 Acyltransferase Metabolic Disease
    Obeversen sodium is an antisense oligonucleotide that inhibits the synthesis of Diacylglycerol acyltransferase 2 (DGAT-2). Obeversen sodium can be used in the research of nonalcoholic fatty liver disease .
    Obeversen sodium
  • HY-148559
    4A3-SC8

    		Liposome Cancer
    4A3-SC8 is a modular degradable dendrimer that enables small RNAs to extend survival in an aggressive liver cancer model .
    4A3-SC8
  • HY-163243
    HSD17B13-IN-29

    		17β-HSD Metabolic Disease
    HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-29

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: